266 384

Cited 0 times in

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

Authors
 Carlos H. Barrios  ;  David Hernandez-Barajas  ;  Michael P. Brown  ;  Se-Hoon Lee  ;  Luis Fein  ;  Jin-Hwang Liu  ;  Subramanian Hariharan  ;  Bridget A. Martell  ;  Jinyu Yuan  ;  Akintunde Bello  ;  Zhixiao Wang  ;  Rajiv Mundayat  ;  Sun-Young Rha 
Citation
 CANCER, Vol.118(5) : 1252-1259, 2012 
Journal Title
CANCER
ISSN
 0008-543X 
Issue Date
2012
MeSH
Adult ; Aged ; Carcinoma, Renal Cell/drug therapy* ; Carcinoma, Renal Cell/epidemiology ; Carcinoma, Renal Cell/mortality ; Carcinoma, Renal Cell/pathology ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Indoles/administration & dosage* ; Indoles/adverse effects ; Kidney Neoplasms/drug therapy* ; Kidney Neoplasms/epidemiology ; Kidney Neoplasms/mortality ; Kidney Neoplasms/pathology ; Male ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Metastasis ; Pyrroles/administration & dosage* ; Pyrroles/adverse effects ; Survival Analysis ; Young Adult
Keywords
renal cell carcinoma ; metastastic ; sunitinib ; continuous dosing ; treatment-naive
Abstract
BACKGROUND: Sunitinib at 50 mg/day on the 4-weeks-on-2-weeks-off schedule is the current approved regimen for advanced/metastatic renal cell carcinoma (mRCC). Escudier et al reported that continuous, once-daily dosing with sunitinib 37.5 mg had a manageable safety profile and significant antitumor activity as second-line mRCC therapy. In this prospective, multicenter, phase II study, we evaluated the activity of continuous once-daily dosing with sunitinib 37.5 mg as first-line mRCC treatment.

METHODS: One hundred nineteen treatment-naive patients with measurable mRCC received sunitinib. The primary endpoint was objective response; secondary endpoints included progression-free survival (PFS), safety, pharmacokinetic measurements, exploration of response biomarkers, and patient reported outcomes (PRO).

RESULTS: Objective response rate (ORR) was 35.3%; median response duration was 10.4 months; 36% of patients had stable disease ≥12 weeks. Median PFS at 1 year was 9 months, and 1-year survival probability was 67.8%. The most common any-grade treatment-related adverse events (AEs) were diarrhea (50%) and hand-foot syndrome (43%); the most common grade 3-4 treatment-related AEs were hand-foot syndrome (13%), neutropenia (11%), and diarrhea (9%). Steady-state pharmacokinetics were reached within 3 weeks, with no disproportionate accumulation of sunitinib or its active metabolite throughout the study. No significant correlations between trough drug, active metabolite, or soluble protein levels and clinical response were observed. PRO was largely maintained, although fatigue appeared to worsen after treatment started, with improvement over time.

CONCLUSIONS: Continuous once-daily dosing with sunitinib 37.5 mg was active with a manageable safety profile as first-line mRCC therapy, making this a feasible alternative dosing regimen.
Files in This Item:
T201202922.pdf Download
DOI
21898376
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/89857
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links